PBLD and systemic lupus erythematosus: Clinically, inhibition of type I IFNs production has been regarded as a promising strategy for the treatment of SLE.[51] Collectively, these results suggest that PBLD may serve as a promising therapeutic target for modulating aberrant type I IFN activity in patients with SLE.